December 2, 2016
Researchers at Memorial Sloan Kettering Cancer Center demonstrated that a new PET imaging agent can detect metastatic prostate cancer in regions that it has previously been difficult to spot. Results from the Phase 1 dose-escalation study of Zr-89-deferrioxamine-IAB2M were published in the December issue of The Journal of Nuclear Medicine.
With an estimated 1.1 million new cases and over 300,000 deaths annually from prostate cancer, it is the second most common cancer among men globally, according to the World Health Organization.
X-ray, CT and MR are traditionally used to determine if prostate cancer has spread to other areas of the body, but it’s often a challenge to image. With this new molecular imaging approach, researchers have shown they can target both bone and soft tissue lesions.